Author

K. Zettl

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:proteomics· 3 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2 Research Focus:differential expression· 1 Approach:experimental assay· 1

Frequent Co-Authors

J. R. Wisniewski· 3 shared A. C. Ramon· 2 shared A. Rodriguez-Ulloa· 2 shared G. V. Perez· 2 shared L. J. Gonzalez· 2 shared M. Rosales· 2 shared S. E. Perea· 2 shared V. Besada· 2 shared

Activity by Year

2021-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. R. Wisniewski

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The response network of HSP70 defines vulnerabilities in cancer cells with the inhibited proteasome

M. Oron, M. Grochowski, A. Jaiswar, J. Legierska, K. Jastrzebski, M. Nowak-Niezgoda, M. Kolos, W. Kazmierczak, T. Olesinski, M. Lenarcik, M. Cybulska, M. Mikula, A. Zylicz, M. Miaczynska, K. Zettl, , D. Walerych

The paper identifies HSP70 as a vulnerability in cancer cells under proteasome inhibition, showing its role in suppressing drug effects and linking its expression to patient risk.

bioRxiv · Nov 16, 2021Cancer Biology

Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300

M. Rosales, G. V. Perez, A. C. Ramon, Y. Cruz, A. Rodriguez-Ulloa, V. Besada, Y. Ramos, D. Vazquez-Blomquist, E. Caballero, D. Aguilar, L. J. Gonzalez, K. Zettl, J. R. Wisniewski, Y. Ke, Y. Perera, S. E. Perea

This study investigates the anti-proliferative and proapoptotic effects of the CK2 inhibitor CIGB-300 on AML cells and identifies its molecular targets.

bioRxiv · May 19, 2021Cancer Biology

Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945

M. Rosales, A. Rodriguez-Ulloa, V. Besada, A. C. Ramon, G. V. Perez, Y. Ramos, O. Guirola, L. J. Gonzalez, K. Zettl, J. R. Wisniewski, Y. Perera, S. E. Perea

This study examines the phosphoproteomic changes in AML cell lines treated with CX-4945, identifying key biological processes and pathways affected by CK2 inhibition.

bioRxiv · Jan 4, 2021Cancer Biology